Clinical characteristics of the pre–B-cell cALL relapse patients
| Patient ID . | Sex . | Age at diagnosis, mo . | Year of diagnosis . | Risk group . | WBC, × 109 /L . | Platelet, × 109 /L . | Treatment protocol . | Radiation . | BMT . | Pre-BMT therapy . | Relapse event number . | Tumor purity, % . | Type . | Event-free survival, d . | Death . | Sequenced events . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | M | 129 | 1995 | High | 2.8 | 323.0 | DFCI 91-01 | Y (after R1) | N | — | 1 | NA|94 | Relapse | 2147 | N | PT|R1 |
| 62 | M | 29 | 1996 | Standard | 22.3 | 85.0 | DFCI 91-01 | Y (after R1) | N | — | 1 | 95|97 | Relapse | 1025 | N | PT|R1 |
| 64 | F | 67 | 1991 | Standard | 3.8 | 30.0 | DFCI 91-01 | N | N | — | 2 | NA|95 | Relapse | 1600 | Y | PT|R1 |
| 217 | F | 23 | 1997 | High | 99.2 | 16.0 | DFCI 95-01 | Y (after R1) | N | — | 1 | 94|87 | Relapse | 259 | Y | PT|R1 |
| 325* | M | 160 | 1999 | High | 7.7 | 12.0 | DFCI 95-01 | N | N | — | 5 | 98|94|95|81|99 | Relapse | 306|106|309|41 | Y | PT|R1|R2|R3|R4 |
| 382 | M | 60 | 2000 | NA | 4.7 | NA | DFCI 95-01 | N | N | — | 3 | 96|70 | Relapse | 534|105 | Y | R1|R2 |
| 391 | M | 35 | 2000 | Standard | 10.0 | 47.0 | DFCI 95-01 | N | N | — | 1 | 98|92 | Relapse | 1143 | N | PT|R1 |
| 394 | F | 92 | 2000 | Standard | 10.5 | 11.0 | DFCI 95-01 | N | N | — | 1 | 99|95 | Relapse | 1189 | N | PT|R1 |
| 445 | F | 45 | 1997 | NA | NA | NA | DFCI 2000-01 | N | Y (after R1) | — | 2 | 97|93 | Refractory (at 2nd induction) | 2227|106 | Y | R1|R2 |
| 447 | F | 129 | 2002 | High | 61.1 | 94.0 | DFCI 2000-01 | N | N | — | 1 | 98|95 | Relapse | 982 | Y | PT|R1 |
| 579* | M | 75 | 2002 | High | 183.1 | 29.0 | DFCI 2000-01 | N | Y (after R1) | Antithymocyte globulin, busulfan, fludarabine | 2 | 96|90|91 | Relapse | 1240|496 | Y | PT|R1|R2 |
| 659 | M | 35 | 2004 | Standard | 29.91 | 24.0 | DFCI 2000-01 | N | N | — | 1 | 100|97 | Relapse | 1420 | N | PT|R1 |
| 670 | M | 33 | 2005 | Standard | 5.48 | 20.0 | DFCI 2005-01 | N | N | — | 1 | 93|94 | Relapse | 1199 | N | PT|R1 |
| 684* | F | 74 | 2005 | NA | 8.49 | 317.0 | DFCI 2005-01 | Y (after R1) | Y (after R1) | Full-body radiation, cyclophosphamide, etoposide | 2 | 84|42|48 | Relapse | 1153|588 | Y | PT|R1|R2 |
| 717 | F | 73 | 2006 | Standard | 5.55 | 24.0 | DFCI 2005-01 | N | N | — | 1 | 100|65 | Relapse | 1380 | Y | PT|R1 |
| 764 | M | 55 | 2008 | High | 59.2 | 21.0 | DFCI 2005-01 | N | N | — | 1 | 96|73 | Relapse | 1107 | N | PT|R1 |
| 772* | M | 39 | 2008 | Standard | 29.72 | 4.0 | DFCI 2005-01 | Y (after R1) | Y (after R1) | Full-body radiation, antithymocyte globulin, cyclophosphamide, etoposide | 2 | 93|45 | Refractory (at 2nd induction) | 736|228 | Y | R1|R2 |
| 786 | M | 206 | 2009 | High | 120.9 | 57.0 | DFCI 2005-01 | N | N | — | 2 | 97|98|95 | Refractory | 35|22 | Y | PT|R1|R2 |
| 808* | M | 15 | 2010 | High | 265.7 | 47.0 | DFCI 2005-01 | Y (after PT) | Y (after PT) | Full-body radiation, antithymocyte globulin, cyclophosphamide, etoposide | 1 | 93|38 | Refractory | 199 | Y | PT|R1 |
| Patient ID . | Sex . | Age at diagnosis, mo . | Year of diagnosis . | Risk group . | WBC, × 109 /L . | Platelet, × 109 /L . | Treatment protocol . | Radiation . | BMT . | Pre-BMT therapy . | Relapse event number . | Tumor purity, % . | Type . | Event-free survival, d . | Death . | Sequenced events . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | M | 129 | 1995 | High | 2.8 | 323.0 | DFCI 91-01 | Y (after R1) | N | — | 1 | NA|94 | Relapse | 2147 | N | PT|R1 |
| 62 | M | 29 | 1996 | Standard | 22.3 | 85.0 | DFCI 91-01 | Y (after R1) | N | — | 1 | 95|97 | Relapse | 1025 | N | PT|R1 |
| 64 | F | 67 | 1991 | Standard | 3.8 | 30.0 | DFCI 91-01 | N | N | — | 2 | NA|95 | Relapse | 1600 | Y | PT|R1 |
| 217 | F | 23 | 1997 | High | 99.2 | 16.0 | DFCI 95-01 | Y (after R1) | N | — | 1 | 94|87 | Relapse | 259 | Y | PT|R1 |
| 325* | M | 160 | 1999 | High | 7.7 | 12.0 | DFCI 95-01 | N | N | — | 5 | 98|94|95|81|99 | Relapse | 306|106|309|41 | Y | PT|R1|R2|R3|R4 |
| 382 | M | 60 | 2000 | NA | 4.7 | NA | DFCI 95-01 | N | N | — | 3 | 96|70 | Relapse | 534|105 | Y | R1|R2 |
| 391 | M | 35 | 2000 | Standard | 10.0 | 47.0 | DFCI 95-01 | N | N | — | 1 | 98|92 | Relapse | 1143 | N | PT|R1 |
| 394 | F | 92 | 2000 | Standard | 10.5 | 11.0 | DFCI 95-01 | N | N | — | 1 | 99|95 | Relapse | 1189 | N | PT|R1 |
| 445 | F | 45 | 1997 | NA | NA | NA | DFCI 2000-01 | N | Y (after R1) | — | 2 | 97|93 | Refractory (at 2nd induction) | 2227|106 | Y | R1|R2 |
| 447 | F | 129 | 2002 | High | 61.1 | 94.0 | DFCI 2000-01 | N | N | — | 1 | 98|95 | Relapse | 982 | Y | PT|R1 |
| 579* | M | 75 | 2002 | High | 183.1 | 29.0 | DFCI 2000-01 | N | Y (after R1) | Antithymocyte globulin, busulfan, fludarabine | 2 | 96|90|91 | Relapse | 1240|496 | Y | PT|R1|R2 |
| 659 | M | 35 | 2004 | Standard | 29.91 | 24.0 | DFCI 2000-01 | N | N | — | 1 | 100|97 | Relapse | 1420 | N | PT|R1 |
| 670 | M | 33 | 2005 | Standard | 5.48 | 20.0 | DFCI 2005-01 | N | N | — | 1 | 93|94 | Relapse | 1199 | N | PT|R1 |
| 684* | F | 74 | 2005 | NA | 8.49 | 317.0 | DFCI 2005-01 | Y (after R1) | Y (after R1) | Full-body radiation, cyclophosphamide, etoposide | 2 | 84|42|48 | Relapse | 1153|588 | Y | PT|R1|R2 |
| 717 | F | 73 | 2006 | Standard | 5.55 | 24.0 | DFCI 2005-01 | N | N | — | 1 | 100|65 | Relapse | 1380 | Y | PT|R1 |
| 764 | M | 55 | 2008 | High | 59.2 | 21.0 | DFCI 2005-01 | N | N | — | 1 | 96|73 | Relapse | 1107 | N | PT|R1 |
| 772* | M | 39 | 2008 | Standard | 29.72 | 4.0 | DFCI 2005-01 | Y (after R1) | Y (after R1) | Full-body radiation, antithymocyte globulin, cyclophosphamide, etoposide | 2 | 93|45 | Refractory (at 2nd induction) | 736|228 | Y | R1|R2 |
| 786 | M | 206 | 2009 | High | 120.9 | 57.0 | DFCI 2005-01 | N | N | — | 2 | 97|98|95 | Refractory | 35|22 | Y | PT|R1|R2 |
| 808* | M | 15 | 2010 | High | 265.7 | 47.0 | DFCI 2005-01 | Y (after PT) | Y (after PT) | Full-body radiation, antithymocyte globulin, cyclophosphamide, etoposide | 1 | 93|38 | Refractory | 199 | Y | PT|R1 |
Information concerning the different relapse events are separated by a bar in the cells.
–, not applicable; BMT, bone marrow transplant; DFCI, Dana-Farber Cancer Institute; F, female; M, male; N, no; NA, not available; Y, yes.
Hypermutable case.